Compugen (CGEN) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
- Market cap
- $200M
- As of Nov 13, 2026
- P/E
- 5.71x
- Latest fiscal year
- P/B
- 1.94x
- Latest reported equity
- P/S
- 2.74x
- Latest fiscal year
- ROE
- 34.0%
- Latest fiscal year
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $200M
- As of Nov 13, 2026
- P/E
- 5.71x
- Latest fiscal year
- P/B
- 1.94x
- Latest reported equity
- P/S
- 2.74x
- Latest fiscal year
- ROE
- 34.0%
- Latest fiscal year
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Latest fiscal year
Latest fiscal-year financials · Computed in-house by ChickenStock
P/E
5.71x
P/B
1.94x
P/S
2.74x
Earnings and dividend metrics▾
Earnings
EPS
$0.37
Earnings per share
BPS
$1.08
Book value per share
ROE
34.0%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $0.37 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $1.08 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 34.0%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
Recent results in a standard quarterly format were not found in SEC filings.
Some foreign companies file only annual or current reports, so quarterly figures may be missing.
See recent SEC filings →Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Perry EranDirector · Jul 29, 2026Grant or award7,500 shares · $0Avg. price $017,500 shares held after
- Halevy GileadDirector · Jul 29, 2026Grant or award7,500 shares · $0Avg. price $018,907 shares held after
- Hukkelhoven MathiasDirector · Jul 29, 2026Grant or award7,500 shares · $0Avg. price $017,500 shares held after
- ZWEIFACH SANFORD SDirector · Jul 29, 2026Grant or award7,500 shares · $0Avg. price $020,180 shares held after
- Kredo Russo SharonSVP, Research & Discovery · Jul 29, 2026Grant or award18,000 shares · $0Avg. price $037,500 shares held after
- Silberman DavidChief Financial Officer · Jul 29, 2026Grant or award19,500 shares · $0Avg. price $055,000 shares held after
- Livnat Savitzky KinneretDirector · Jul 29, 2026Grant or award7,500 shares · $0Avg. price $020,850 shares held after
- Mahler MichelleChief Medical Officer · Jul 29, 2026Grant or award13,500 shares · $0Avg. price $036,625 shares held after
- Levine ZuritSVP, Business Development · Jul 29, 2026Grant or award18,000 shares · $0Avg. price $047,375 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Compugen (CGEN) stock information
NASDAQ
Compugen (CGEN) is listed on NASDAQ. Its market capitalization is about $200M. On trailing-twelve-month earnings the P/E ratio is 5.71, and the P/B ratio is 1.94. Return on equity is 34%. These figures are computed in-house from official filings and are reference information only.
Compugen — frequently asked questions
- What is the P/E ratio of Compugen (CGEN)?
- On a trailing-twelve-month basis, CGEN trades at a P/E ratio of 5.71. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Compugen?
- CGEN has a market capitalization of about $200M. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.